ArticleCancers2021
Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment.Nutrients · 2023Pooled it
- Sarcopenia as a risk factor of progression-free survival in patients with metastases: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- Skeletal muscle radiodensity as an automated survival predictor in men with metastatic castration-resistant prostate cancer undergoing PSMA-targeted radioligand therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Inflammaging: Immune-Metabolic Crosstalk Between the Prostate-Testis and Musculoskeletal System.International journal of molecular sciences · 2026Review
- A predictive model for differentiating PFA and PFB subtypes of posterior fossa ependymoma using multi-sequence MRI radiomics: a two-center study.Neuroradiology · 2026Article
- Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer.Prostate cancer · 2025Article
- Sarcopenia and lower urinary tract diseases: links, mechanisms, and clinical implications.Frontiers in nutrition · 2025Review
- Prevalence and impact of sarcopenia on urinary incontinence in localized prostate cancer patients undergoing laparoscopic radical prostatectomy.Frontiers in urology · 2025Article
- Psoas mass index at the level of the third lumbar vertebra on computed tomography is a prognostic predictor for metastatic castration-sensitive prostate cancer.International journal of clinical oncology · 2024Article
- Advances in sarcopenia and urologic disorders.Frontiers in nutrition · 2024Review
- Low Alanine Aminotransferase, as a Marker of Sarcopenia and Frailty, Is Associated with Shorter Survival Among Prostate Cancer Patients and Survivors. A Retrospective Cohort Analysis of 4064 Patients.European urology open science · 2023Article
- Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer.Cancer medicine · 2023Article
- Article
- Long-term neurocognitive function after whole-brain radiotherapy in patients with melanoma brain metastases in the era of immunotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2022Article
- Impact of sarcopenia in bladder preservation therapy for muscle-invasive bladder cancer patients: a narrative review.Translational andrology and urology · 2022Review
- Prognostic Significance of Myopenia, Myosteatosis, and Frailty in Older Patients With Prostate Cancer Undergoing Definitive Radiotherapy.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
The clinical value of sarcopenia has not been determined yet in metastatic hormone-sensitive prostate cancer (mHSPC). We retrospectively evaluated data of 70 consecutive patients with mHSPC receiving treatment with either early docetaxel (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.